Interim report 1 January – 30 September 2024

Organic growth and stable margin while profitability improvement initiatives are progressing

Continued organic growth and stable margin in the third quarter - a quarter that is normally somewhat weaker seasonally. The work on profitability improvements is progressing according to plan.

Fredrik Dalborg, President and CEO

1 JULY– 30 SEPTEMBER 2024 (3 MONTHS)

- Net sales increased by 1% to SEK 2,344m (2,319). The organic growth, excluding exchange rate changes, was 3% and the acquired growth was 1%.
- EBITA decreased by 9% to SEK 223m (244), corresponding to an EBITA-margin of 9.5% (10.5). Adjusted for revalued contingent considerations and restructuring costs, EBITA amounted to SEK 230m (227), corresponding to an EBITA-margin of 9.8% (9.8).
- Profit after tax amounted to SEK 25m (26).
- Earnings per share amounted to SEK 0.19 (0.20).
- Cash flow from operating activities amounted to SEK 137m (138).
- During the quarter an acquisition, BonsaiLab SLU, was completed. The acquisition is estimated to contribute with an annual net sale of approximately SEK 90m.

3 %
ORGANIC GROWTH
Q3 2024

1 JANUARY – 30 SEPTEMBER 2024 (9 MONTHS)

- Net sales increased by 5% to SEK 7,468m (7,141). The organic growth, excluding exchange rate changes, was 5%.
- EBITA decreased by 5% to SEK 813m (857), corresponding to an EBITA-margin of 10.9% (12.0). Adjusted for revalued contingent considerations and restructuring costs, EBITA amounted to SEK 819m (756). Excluding these, EBITA increased by 8% and the EBITA-margin amounted to 11.0% (10.6).
- Profit after tax amounted to SEK 160m (233).
- Earnings per share amounted to SEK 1.30 (1.90). Earnings per share for the last 12 months amounted to SEK 0.98 (2.40)
- Cash flow from operating activities amounted to SEK 429m (325).
- The equity ratio was 40% (39).
- Return on working capital (P/WC) amounted to 47% (50).

5 %
ORGANIC GROWTH
9 m 2024

SEKm	3 months ending 30 Sep 24	3 months ending 30 Sep 23	change	9 months ending 30 Sep 24	9 months ending 30 Sep 23	change	12 months ending 30 Sep 24	12 months ending 31 Dec 23
Net sales	2,344	2,319	1%	7,468	7,141	5%	10,012	9,685
EBITA	223	244	-9%	813	857	-5%	1,091	1,135
EBITA-margin	9.5%	10.5%		10.9%	12.0%		10.9%	11.7%
Profit before tax	42	61	-32%	255	337	-24%	257	339
Profit for the period	25	26	-4%	160	233	-31%	119	192
Earnings per share before dilution, SEK	0.19	0.20	-5%	1.30	1.90	-32%	0.98	1.56
Earnings per share after dilution, SEK	0.19	0.20	-5%	1.30	1.90	-32%	0.98	1.56

NET SALES (SEKM)



EBITA (SEKM)



One-off costs, SEKm	3 months ending 30 Sep 24	3 months ending 30 Sep 23	9 months ending 30 Sep 24	9 months ending 30 Sep 23
Restructuring reserve Camanio Health	-4	–	-10	–
Revalued contingent consideration	-3	17	4	101
Total one-off costs	**-7**	**17**	**-6**	**101**

Classification in income statement, SEKm	3 months ending 30 Sep 24	3 months ending 30 Sep 23	9 months ending 30 Sep 24	9 months ending 30 Sep 23
Selling expenses	-1	–	-2	–
Administrative expenses	-1	–	-3	–
Research and Development	-2	–	-5	–
Other operating income and expenses	-3	17	4	101
Total one-off costs in the income statement	**-7**	**17**	**-6**	**101**

COMMENTS BY THE CEO

Sales in both business areas were stable during the summer months of the third quarter - a quarter when we typically see seasonally lower activity in diagnostics, research, and in particular elective surgery.

In Labtech, sales of consumables were stable and growing, but particularly in research, our companies continued to see some delays in capital investments, which affected instrument sales in the quarter. As we have seen before, this is not about cancelled or lost deals, but rather orders that have been postponed and are expected in upcoming quarters. This, combined with the fact that sales of newly launched products in some companies developed somewhat slower than planned, led to Labtech's margins being lower in the third quarter compared to the same quarter last year. At the same time, we secured several important tenders for established products with good profitability during the quarter.

Patient waiting lists did not decrease in the quarter and growth in Medtech was somewhat restrained by the relatively low number of surgeries performed. The lower number of surgeries was due to seasonal effects, since fewer surgeries are planned during the summer months, but was also a result of healthcare strikes, staff shortages, and politically driven changes in healthcare in several countries.

However, the underlying patient need remains, as does the political will to address the issues, which makes us optimistic about future activity levels in planned surgery.

Adjusted for revalued contingent considerations and restructuring costs in Camanio, the margin in Medtech improved, and is now established at a higher level during the year. Excluding these items, the EBITA result and margin for the group were at the same level compared to the previous year, and the growth is good in relation to the market conditions.

> *Sales in both business areas were stable during the third quarter - a quarter when we typically see seasonally lower activity during the summer months.*

Continued progress in profitability improvements and cash flow.
Profitability improvements remain the highest priority, and this work is being driven forward firmly and is developing according to plan.

The cost level in AddVision has decreased significantly, and the business has returned to profitability. At this stage, the main focus is on commercial development. Product portfolios have been updated, production capacity increased, collaboration with suppliers intensified, and sales of new products have developed well. During the quarter, we also implemented planned organizational changes for improved commercial focus and increased efficiency.

The closure of Camanio was completed during the third quarter as planned, and the negative impact on results, which amounted to approximately SEK 15m per quarter, will be completely gone from the fourth quarter of 2024.

Efforts to improve cash flow are being systematically driven within the companies. The cash flow is stable, cash conversion has improved, and the work on further efficiencies continues.

Acquisitions in line with our strategy contribute positively.
At the beginning of the third quarter, BonsaiLab, a Spanish company active in biotechnology that provides a product portfolio with market-leading instruments and consumables in cell and molecular biology, was acquired. We are very pleased to have welcomed BonsaiLab to AddLife. The business is developing well, has favourable market conditions, and good profitability. The work of evaluating several similar acquisitions, which contribute to increased growth and profitability, continues with high intensity.

Summary
Organic growth continues in the seasonally weaker third quarter, despite some delays in instrument sales. The margin in Labtech was low, explained by delayed instrument sales, which are expected to recover over time. The positive trend for the margin in Medtech continues, and in the next quarter, we will see the effect of the closure of Camanio.

We look forward with confidence to a seasonally stronger fourth quarter and continued focused efforts on acquisitions in line with our strategy.

As always, I would like to take this opportunity to thank all employees for your dedicated work and significant contributions during the quarter!

Fredrik Dalborg

President and CEO

Group Performance in the quarter

Net sales in the quarter increased by 1 percent to SEK 2,344m (2,319). Organic growth, excluding exchange rate effects, was 3 percent and the acquired growth was 1 percent. Exchange rate effects negatively impacted net sales by 3 percent in the quarter, corresponding to SEK 59m.

NET SALES 3 MONTHS



EBITA decreased by 9 percent to SEK 223m (244) and the EBITA-margin was 9.5 percent (10.5). EBITA for the quarter was negatively affected by a revalued contingent consideration of SEK 3 m and restructuring costs of SEK 4m. The previous year's interim period was positively affected by revalued contingent considerations of SEK 17m. Excluding these, EBITA for the quarter amounted to SEK 230m (227) and the EBITA-margin amounted to 9.8 percent (9.8). Exchange rate fluctuations negatively impacted EBITA by SEK 7m.

EBITA 3 MONTHS



Net financial items amounted to SEK -72m (-71) and profit after financial items amounted to SEK 42m (61). Net financial items primarily include interest expenses related to financing of previous acquisitions and exchange rate fluctuations. Net interest amounted to SEK -77m (-71) and exchange rate gains to SEK 8m (5). The profit after tax for the quarter was SEK 25m (26) and the effective tax rate was 40 percent (57). The high effective tax rate is attributable to the effect of non-deductible interest.

Group Performance in the period

Net sales for the interim period increased by 5 percent to SEK 7,468m (7,141). Organic growth, excluding exchange rate effects, was 5 percent. Exchange rate fluctuations and acquisitions had a marginally negative impact on net sales during the interim period, corresponding to SEK 22m.

NET SALES 9 MONTHS



EBITA decreased by 5 percent to SEK 813m (857) and the EBITA-margin amounted to 10.9 percent (12.0). During the interim period, EBITA was affected by a total of SEK -6m (101) from revalued contingent considerations and restructuring costs. Excluding these EBITA increased by 8 percent and the EBITA-margin amounted to 11.0 percent (10.6). Exchange rate fluctuations had a marginally negative impact on EBITA, corresponding to SEK 3m.

EBITA 9 MONTHS



Net financial items amounted to SEK -237m (-189) and profit after financial items was SEK 255m (337). Net financial items include interest costs related to financing of previous acquisitions and exchange rate fluctuations. Net interest amounted to SEK -225m (-196) and exchange rate gains to SEK 1m (14). The profit after tax for the period was SEK 160m (233) and the effective tax rate was 37 percent (31). The high effective tax rate is attributable to the effect of non-deductible interest.

The geopolitical situation in Ukraine and the Middle East has not had any significant financial impact on the financial reports, but it cannot be ruled out that this will happen in the future. We are closely monitoring market developments regarding inflation, raw material, component, freight, and energy costs, as well as interest rate trends.

Financial position and cash flow

At the end of the interim period, the equity ratio stood at 40 percent (39). Equity per share totalled SEK 42.07 (40.69) and the return on equity at the end of the interim period was 2 percent (4). Return on working capital, P/WC (EBITA in relation to working capital) amounted to 47 percent (50).

The group's interest-bearing net debt at the end of the interim period amounted to SEK 5,350m (5,192), including pension liabilities of SEK 63m (64), leasing liabilities of SEK 520m (498) and contingent considerations corresponding to SEK 106m (87). Outstanding bank loans at the end of the interim period amounted to SEK 4,811m (4,698). The credit facilities of SEK 1,000m and EUR 98.2m, respectively, due in the first quarter of 2025, have been extended by 12 months and have an extension option of another 12 months.

The group has a good margin in the covenants applicable under the banking agreements, which stipulate an interest coverage ratio of at least 4.0 times and an equity ratio exceeding 25 percent. As of the end of the interim period, the interest coverage ratio amounted to 5.4 times, as defined in the bank agreements.

The net debt/equity ratio totalled 1.0 compared to 1.0 at the beginning of the interim period. The intention is to reduce debt through self-generated cash flow.

Cash and cash equivalents, consisting of cash and bank balances, together with approved but non-utilised credit facilities, totalled SEK 839m (1,013) on September 30, 2024.

The cash flow from current operations during the quarter amounted to SEK 137m (138) and during the interim period to SEK 429m (325), mainly attributable to a higher result after financial items. Acquisition of operations amounted to SEK 53m (13). Paid out contingent consideration related to acquisitions of companies in previous years amounted to SEK 42m (16). Net investments in non-current assets during the interim period amounted to SEK 177m (195) and are mainly attributable to investments in instruments for rental to customers. Exercised, issued and repurchased call options amounted to SEK -12 m (-9). A dividend of SEK 61m (146) has been paid to the parent company´s shareholders.

LONG TERM FINANCIAL GOALS

PROFITABILITY P/WC (%)



PROFIT GROWTH (%)



Acquisitions

Acquisitions completed from the 2023 financial year are distributed among the group's business areas as follows:

Acquisitions	Time	Net Sales, SEKm*	Number of employees*	Business area
Emmat Medical Ltd, Great Britain	September, 2023	28	4	Medtech
BonsaiLab, Spain	July, 2024	90	13	Labtech
		118	**17**	

** Refers to conditions at the time of acquisition on a full-year basis.*

On July 4, 2024, AddLife AB acquired all shares in the Spanish company BonsaiLab. BonsaiLab is a leading Spanish distributor in cell and molecular biology and provides a product portfolio of market-leading instruments and consumables in cell and molecular biology. The company has a turnover of approximately EUR 8m and has 13 employees.

The acquisition that was completed during the year has overall affected the group's net sales by SEK 23m, EBITA by SEK 5m, the operating profit by SEK 3m and the period's profit after tax by SEK 2m. The acquisition would have affected the group's net sales by an estimated SEK 78m, EBITA by SEK 15m, operating profit by SEK 11m and the year's profit after tax by SEK 8m if they had been implemented on January 1, 2024.

The assets and liabilities that were included in the completed acquisitions during the financial year 2024 amount, according to the preliminary and determined acquisition analyses, to the following:

Fair value	Total
Intangible non-current assets	56
Other non-current assets	0
Inventories	7
Other current assets	33
Deferred tax liability/tax asset	-14
Other liabilities	-25
Acquired net assets	**57**
Goodwill	68
Consideration[1]	125
Less: cash and cash equivalents in acquired businesses	-10
Contingent consideration not yet paid	-62
Effect on the Group's cash and cash equivalents	**53**

[1] The consideration is stated excluding acquisition expenses.

The goodwill that has arisen in connection with the acquisitions is due to the fact that the group's position in the current market is expected to be strengthened and to the knowledge that has been developed in the acquired companies. Transaction costs for acquisitions total SEK 2m and are reported in the item sales costs.

Revaluation of liabilities for contingent considerations related to previous acquisitions in the Medtech Business Area has resulted in an income of SEK 4m. During the interim period, these have been revalued and reported in other operating income. Contingent consideration amounting to SEK 42m has been paid during the interim period regarding BioConnect, Funksjonsutstyr, O'Flynn and JKLab, which were acquired in previous years.

Employees

At the end of the interim period, the number of employees was 2,356, compared to 2,301 at the beginning of the financial year. The average number of employees for the last 12-month period was 2,315 (2,269).

BUSINESS AREA

Labtech

Companies in the Labtech business area are active in the market areas diagnostics, biomedical research and laboratory equipment.

	3 months ending			9 months ending			12 months ending	
SEKM	**30 Sep 24**	**30 Sep 23**	**change**	**30 Sep 24**	**30 Sep 23**	**change**	**30 Sep 24**	**31 Dec 23**
Net sales	852	827	3%	2,656	2,604	2%	3,706	3,654
Organic growth, %	3%	9%		2%	9%			10%
EBITA	76	99	-23%	284	321	-12%	436	473
EBITA-margin	8.9%	12.0%		10.7%	12.3%		11.8%	12.9%

Labtech's net sales increased by 3 percent in the third quarter to SEK 852m (827). The organic sales growth amounted to 3 percent and the acquired growth amounted to 3 percent. Exchange rate changes had a negative impact of 3 percent on net sales. EBITA decreased by 23 percent to SEK 76m (99), corresponding to an EBITA-margin of 8.9 percent (12.0). EBITA the previous year was positively affected by the reversed contingent consideration of SEK 15m. Adjusted for this, the EBITA-margin last year was 10.2%

NET SALES 3 MONTHS



Labtech's net sales increased by 2 percent in the interim period to SEK 2,656m (2,604), whereof the organic sales growth amounted to 2 percent and the acquired growth amounted to 1 percent. Exchange rate changes had a negative impact of 1 percent on net sales. EBITA decreased by 12 percent to SEK 284m (321), corresponding to an EBITA-margin of 10.7 percent (12.3).

NET SALES 9 MONTHS



Sales increased by 3 percent organically in the third quarter, which is typically the quarter with the lowest activity during the year. The sales of consumables have a high degree of stability in both diagnostics and research, and this was also the case during the third quarter. However, instrument sales were lower due to fewer procurement decisions and installations occurring during the summer. Additionally, staff shortages in procurement departments, uncertainty regarding research budgets, and slower sales growth for newly launched products negatively impacted instrument sales in the quarter. The assessment remains that instrument sales are delayed, not cancelled.

Demand from pharmaceutical companies remains strong, resulting in an increasing share of sales going to pharmaceutical companies while the share of sales to academic research decreases.

The weaker sales of more advanced instruments for research purposes, in particular, also had a negative effect on the margin in the quarter.

Several important tenders were secured during the third quarter, with deliveries expected to start in the fourth quarter.

In Eastern Europe, invoicing in the third quarter was weaker, similar to last year, with an expectation of a strong finish to the year.

NET SALES (SEKM)



NET SALES PER MARKET 2024



EBITA (SEKM)



EBITA-MARGIN (%)



BUSINESS AREA

Medtech

Companies in the Medtech business area provide medical device products within the medtech market and assistive equipment within Homecare.

	3 months ending			9 months ending			12 months ending	
MSEK	**30 Sep 24**	**30 Sep 23**	**change**	**30 Sep 24**	**30 Sep 23**	**change**	**30 Sep 24**	**31 Dec 23**
Net sales	1,494	1,494	0%	4,817	4,544	6%	6,315	6,042
Organic growth, %	3%	10%		6%	10%			9%
EBITA	153	150	3%	551	551	0%	684	684
EBITA-margin	10.3%	10.0%		11.4%	12.1%		10.8%	11.3%

Net sales within Medtech amounted to SEK 1,494m during the third quarter, which is unchanged from the corresponding period last year. Organic growth amounted to 3 percent and exchange rate changes negatively affected net sales by 3 percent. EBITA increased by 3 percent to SEK 153m (150), corresponding to an EBITA-margin of 10.3 percent (10.0). EBITA was negatively affected by the revaluation of contingent considerations of SEK 7m and restructuring costs in Camanio. Adjusted for this the EBITA-margin amounted to 10.7 percent. During the quarter Camanio has negatively affected the result by SEK 10m (12), of which SEK 4m refers to restructuring costs related to the closure of the company. From the fourth quarter, the result will not be burdened with any additional costs.

NET SALES 3 MONTHS



In the interim period, net sales increased by 6 percent to SEK 4,817m (4,544), of which organic growth was 6 percent. Exchange rate changes affected net sales marginally. EBITA amounted to SEK 551m (551), corresponding to an EBITA-margin of 11.4 percent (12.1). EBITA was negatively affected by the revaluation of contingent considerations and restructuring costs related to Camanio of SEK 6m (+86). Adjusted for these the EBITA-margin amounted to 11.6 percent (10.3). Camanio has had a negative impact on the result with SEK 39m (43), of which SEK 10m refers to a restructuring reserve related to the successive closure of the company, which has now been completed.

NET SALES 9 MONTHS



The number of elective surgery procedures was low during the summer months in line with normal seasonal variations, and organic growth was 3 percent in the quarter.

Patient waiting lists in the countries where AddLife's companies operate have not decreased during the quarter. In the UK, the number of patients waiting for surgeries is essentially unchanged, but there is a clear expectation of reforms and investments in healthcare following the election. These have not yet been implemented but are expected to have a positive effect in 2025.

In the Nordics, the number of surgeries has also been relatively low in the quarter due to seasonal variations, as well as ongoing staff shortages. In some countries, there is a noticeable delay regarding capital investments.

The margin strengthened to 10.7% (10.0), thanks to good cost control and strong growth in advanced products with higher profitability.

The work on profitability improvement initiatives within AddVision continue, and planned organizational changes have been implemented during the quarter. Product portfolios have been more focused on profitable products while less profitable ones have been phased out, leading to reduced sales but better margins.

The closure of Camanio was completed during the third quarter as planned, after all users were migrated to other solutions. The negative result effect, which amounted to approximately SEK 15m per quarter, will be completely gone from the fourth quarter of 2024.

NET SALES (SEKM)



NET SALES PER MARKET 2024



EBITA (SEKM)



EBITA-MARGIN (%)



AddLife

Net sales by business area

Quarterly data, SEKm	Q3	Q2	2024 Q1	Q4	Q3	Q2	2023 Q1
Labtech	852	941	863	1,050	827	872	905
Medtech	1,494	1,615	1,708	1,498	1,494	1,496	1,554
Group items	-2	-2	-1	-4	-2	-3	-2
AddLife Group	**2,344**	**2,554**	**2,570**	**2,544**	**2,319**	**2,365**	**2,457**

EBITA by business area

Quarterly data, SEKm	Q3	Q2	2024 Q1	Q4	Q3	Q2	2023 Q1
Labtech	76	109	99	152	99	107	115
Medtech	153	200	198	133	150	145	256
Parent Company and Group items	-6	-10	-6	-7	-5	-5	-5
EBITA	**223**	**299**	**291**	**278**	**244**	**247**	**366**
Depreciation and write-down intangible assets	-109	-107	-105	-219	-112	-111	-108
Operating profit	**114**	**192**	**186**	**59**	**132**	**136**	**258**
Finance income and expenses	-72	-79	-86	-57	-71	-66	-52
Profit after financial items	**42**	**113**	**100**	**2**	**61**	**70**	**206**

EBITA by business area excluding items affecting comparability

Quarterly data, SEKm	Q3	Q2	2024 Q1	Q4	Q3	Q2	2023 Q1
Labtech	76	109	99	152	84	107	115
Medtech	160	193	204	114	148	145	173
Parent Company and Group items	-6	-10	-6	-7	-5	-5	-5
EBITA	**230**	**292**	**297**	**259**	**227**	**247**	**283**
Depreciation and write-down intangible assets	-109	-107	-105	-113	-112	-111	-108
Operating profit	**121**	**185**	**192**	**146**	**115**	**136**	**175**
Finance income and expenses	-72	-79	-86	-57	-71	-66	-52
Profit after financial items	**49**	**106**	**106**	**89**	**44**	**70**	**123**

Net sales by business area

	3 months ending			9 months ending			12 months ending	
SEKm	**30 Sep 24**	**%**	**30 Sep 23**	**30 Sep 24**	**%**	**30 Sep 23**	**30 Sep 24**	**31 Dec 23**
Labtech	852	3	827	2,656	2	2,604	3,706	3,654
Medtech	1,494	0	1,494	4,817	6	4,544	6,315	6,042
Group items	-2		-2	-5		-7	-9	-11
AddLife Group	**2,344**	**1**	**2,319**	**7,468**	**5**	**7,141**	**10,012**	**9,685**

EBITA and EBITA-margin by business area and operating profit for the group

	3 months ending				9 months ending				12 months ending			
SEKm	**30 Sep 24**	**%**	**30 Sep 23**	**%**	**30 Sep 24**	**%**	**30 Sep 23**	**%**	**30 Sep 24**	**%**	**31 Dec 23**	**%**
Labtech	76	8.9	99	12.0	284	10.7	321	12.3	436	11.8	473	12.9
Medtech	153	10.3	150	10.0	551	11.4	551	12.1	684	10.8	684	11.3
Parent Company and Group items	-6		-5		-22		-15		-29		-22	
EBITA	**223**	**9.5**	**244**	**10.5**	**813**	**10.9**	**857**	**12.0**	**1,091**	**10.9**	**1,135**	**11.7**
Depreciation and write-down intangible assets	-109		-112		-321		-331		-540		-550	
Operating profit	**114**	**4.9**	**132**	**5.7**	**492**	**6.6**	**526**	**7.4**	**551**	**5.5**	**585**	**6.0**
Finance income and expenses	-72		-71		-237		-189		-294		-246	
Profit after financial items	**42**		**61**		**255**		**337**		**257**		**339**	

Net sales by revenue type

	3 months ending		9 months ending		12 months ending	
SEKm	**30 Sep 24**	**30 Sep 23**	**30 Sep 24**	**30 Sep 23**	**30 Sep 24**	**31 Dec 23**
Products	618	579	1,932	1,857	2,623	2,548
Instruments	170	179	515	544	775	804
Service	64	69	209	203	308	302
Labtech	**852**	**827**	**2,656**	**2,604**	**3,706**	**3,654**
Products	1,196	1,240	3,901	3,737	5,076	4,912
Instruments	128	124	415	407	513	505
Service	170	130	501	400	726	625
Medtech	**1,494**	**1,494**	**4,817**	**4,544**	**6,315**	**6,042**
Group items	-2	-2	-5	-7	-9	-11
Total	**2,344**	**2,319**	**7,468**	**7,141**	**10,012**	**9,685**

Sales per country

	3 months ending		9 months ending		12 months ending	
	30 Sep 24	**30 Sep 23**	**30 Sep 24**	**30 Sep 23**	**30 Sep 24**	**31 Dec 23**
UK	318	348	1,024	918	1,292	1,186
Ireland	301	253	949	845	1,218	1,114
Sweden	239	247	791	815	1,076	1,100
Spain	207	174	701	607	920	826
Norway	186	181	610	579	815	784
Denmark	169	171	511	525	779	793
Italy	156	149	484	474	672	662
Finland	135	130	403	416	564	577
Rest of Europe	576	558	1,740	1,710	2,381	2,351
Rest of the world	57	108	255	252	295	292
Total	**2,344**	**2,319**	**7,468**	**7,141**	**10,012**	**9,685**

Consolidated income statement, condensed

Income statement	3 months ending		9 months ending		12 months ending	
SEKm	30 Sep 24	30 Sep 23	30 Sep 24	30 Sep 23	30 Sep 24	31 Dec 23
Net sales	2,344	2,319	7,468	7,141	10,012	9,685
Cost of sales	-1,470	-1,460	-4,653	-4,461	-6,278	-6,086
Gross profit	**874**	**859**	**2,815**	**2,680**	**3,734**	**3,599**
Selling expenses	-602	-594	-1,840	-1,805	-2,513	-2,478
Administrative expenses	-141	-137	-443	-423	-608	-588
Research and Development	-20	-21	-61	-70	-158	-167
Other operating income and expenses	3	25	21	144	96	219
Operating profit	**114**	**132**	**492**	**526**	**551**	**585**
Financial income and expenses	-72	-71	-237	-189	-294	-246
Profit after financial items	**42**	**61**	**255**	**337**	**257**	**339**
Tax	-17	-35	-95	-104	-138	-147
Profit for the period	**25**	**26**	**160**	**233**	**119**	**192**
Attributable to:						
Equity holders of the Parent Company	24	25	158	231	117	190
Non-controlling interests	1	1	2	2	2	2
Earnings per share (EPS) before dilution, SEK	0.19	0.20	1.30	1.90	0.98	1.56
Earnings per share (EPS) after dilution, SEK	0.19	0.20	1.30	1.90	0.98	1.56
Average number of shares after repurchases '000s	121,864	121,857	121,863	121,856	121,861	121,856
Number of shares at end of the period, '000	121,864	121,857	121,864	121,857	121,864	121,857
EBITA	223	244	813	857	1,091	1,135
Depreciations and write-down included in operating expenses						
- property, plant and equipment	-92	-88	-276	-255	-390	-369
- intangible non-current assets from acquisitions	-99	-103	-294	-302	-442	-450
- other intangible non-current assets	-10	-9	-27	-29	-98	-100

Statement of comprehensive income

SEKm	3 months ending 30 Sep 24	3 months ending 30 Sep 23	9 months ending 30 Sep 24	9 months ending 30 Sep 23	12 months ending 30 Sep 24	12 months ending 31 Dec 23
Profit for the period	**25**	**26**	**160**	**233**	**119**	**192**
Components that may be reclassified to profit for the period						
Foreign currency translation differences for the period	-37	-137	83	143	-101	-41
Components that can not be reclassified to profit for the period						
Revaluations of defined benefit pension plans	–	–	–	–	-4	-4
Tax attributable to items not to be reversed in profit or loss	–	–	–	–	1	1
Other comprehensive income	**-37**	**-137**	**83**	**143**	**-104**	**-44**
Total comprehensive income	**-12**	**-111**	**243**	**376**	**15**	**148**
Attributable to:						
Equity holders of the Parent Company	*-13*	*-111*	*241*	*375*	*11*	*145*
Non-controlling interests	*1*	*0*	*2*	*1*	*4*	*3*

Consolidated balance sheet, condensed

SEKm	30 Sep 24	31 Dec 23	30 Sep 23
Goodwill	5,451	5,303	5,467
Other intangible non-current assets	2,478	2,662	2,935
Property, plant and equipment	1,078	1,051	927
Financial non-current assets	129	121	131
Total non-current assets	**9,136**	**9,137**	**9,460**
Inventories	1,750	1,653	1,833
Current receivables	1,793	1,683	1,797
Cash and cash equivalents	264	272	229
Total current assets	**3,807**	**3,608**	**3,859**
Total assets	**12,943**	**12,745**	**13,319**
Total equity	**5,129**	**4,960**	**5,188**
Interest-bearing provisions	177	174	177
Non-interest-bearing provisions	374	415	444
Non-current interest-bearing liabilities	4,034	2,886	2,866
Non-current non-interest-bearing liabilities	5	5	8
Total non-current liabilities	**4,590**	**3,480**	**3,495**
Non-interest-bearing provisions	45	46	49
Current interest-bearing liabilities	1,403	2,403	2,786
Current non-interest-bearing liabilities	1,776	1,856	1,801
Total current liabilities	**3,224**	**4,305**	**4,636**
Total equity and liabilities	**12,943**	**12,745**	**13,319**

Statement of change in Group equity

Statement of change in Group equity, SEKm	1 Jan 24 – 30 Sep 24			1 Jan 23 – 31 Dec 23		
	Equity excl. non-controlling interests	Non-controlling interests	Total equity	Equity excl. non-controlling interests	Non-controlling interests	Total equity
Amount at beginning of period	4,958	2	4,960	4,968	3	4,971
Exercised and issued call options	-12	–	-12	-9	–	-9
Share-based payments	0	–	0	–	–	–
Dividend	-61	-1	-62	-146	-4	-150
Total comprehensive income	241	2	243	145	3	148
Amount at the end of the period	**5,126**	**3**	**5,129**	**4,958**	**2**	**4,960**

Cash flow statement, condensed

Cash flow statement, condensed	3 months ending		9 months ending		12 months ending	
SEKm	30 Sep 24	30 Sep 23	30 Sep 24	30 Sep 23	30 Sep 24	31 Dec 23
Profit after financial items	42	61	255	337	257	339
Adjustment for items not included in cash flow	201	166	554	465	797	708
Income tax paid	-33	-42	-92	-149	-153	-210
Changes in working capital	-73	-47	-288	-328	-24	-64
Cash flow from operating activities	**137**	**138**	**429**	**325**	**877**	**773**
Net investments in non-current assets	-50	-64	-177	-195	-268	-286
Acquisitions and disposals	-54	-13	-93	-29	-95	-31
Cash flow from investing activities	**-104**	**-77**	**-270**	**-224**	**-363**	**-317**
Dividend paid to shareholders	–	–	-61	-146	-61	-146
Dividend paid to non-controlling interests	–	–	-1	-4	-1	-4
Exercised and issued call options	–	8	-12	-9	-12	-9
Borrowings	42	5	69	171	72	174
Repayments on loans	-8	-99	-43	-131	-319	-407
Other financing activities	-39	-3	-134	-152	-144	-162
Cash flow from financing activities	**-5**	**-89**	**-182**	**-271**	**-465**	**-554**
Cash flow for the period	28	-28	-23	-170	49	-98
Cash and cash equivalents at beginning of period	**242**	**267**	**272**	**376**	**229**	**376**
Exchange differences on cash and cash equivalents	-6	-10	15	23	-14	-6
Cash and cash equivalents at end of the period	**264**	**229**	**264**	**229**	**264**	**272**

Key financial indicators

	12 months up until				
	30 Sep 24	**31 Dec 23**	**30 Sep 23**	**31 Dec 22**	**31 Dec 21**
Net sales, SEKm	10,012	9,685	9,467	9,084	7,993
EBITDA, SEKm	1,481	1,504	1,454	1,530	1,474
EBITA, SEKm	1,091	1,135	1,115	1,221	1,273
EBITA-margin, %	10.9%	11.7%	11.8%	13.4%	15.9%
Profit growth, EBITA, %	-2%	-7%	-14%	-4%	59%
Return on working capital (P/WC), %	47%	50%	49%	61%	95%
Profit for the period, SEKm	119	192	295	483	721
Return on equity, %	2%	4%	6%	10%	22%
Financial net liabilities, SEKm	5,350	5,192	5,600	5,410	3,870
Financial net liabilities/EBITDA, multiple	3.6	3.5	3.9	3.5	2.6
Net debt/equity ratio, multiple	1.0	1.0	1.1	1.1	0.9
Equity ratio, %	40%	39%	39%	38%	40%
Average number of employees	2,315	2,284	2,269	2,157	1,548
Number of employees at end of the period	2,356	2,301	2,314	2,219	1,802

Key ratio definitions can be found here.

Key financial indicators per share

	12 months up until				
	30 Sep 24	**31 Dec 23**	**30 Sep 23**	**31 Dec 22**	**31 Dec 21**
Earnings per share (EPS), before dilution, SEK	0.98	1.56	2.40	3.96	6.03
Earnings per share (EPS), after dilution, SEK	0.98	1.56	2.40	3.95	6.01
Cash flow per share from operating activities, SEK	7.20	6.35	5.54	7.46	8.46
Shareholders' equity per share, SEK	42.07	40.69	42.63	40.76	35.14
Average number of shares after repurchases, '000s	121,861	121,856	121,846	121,779	119,418
Average number of shares adjusted for repurchases and dilution, '000s	121,861	121,861	121,918	122,254	119,966
Number of shares outstanding at end of the period, '000s	121,864	121,857	121,857	121,836	121,953
Number of shares outstanding at end of the period after dilution, '000s	121,864	121,857	121,929	122,312	122,501

Parent company

The Parent Company's net sales for the interim period amounted to SEK 56m (48) and profit after financial items amounted to SEK -6m (111). At the end of the interim period the Parent Company's net financial debt amounted to SEK 4,718m (4,591). The share capital at the end of the interim period was SEK 62m (62).

Income statement

	3 months ending		9 months ending		12 months ending	
SEKm	**30 Sep 24**	**30 Sep 23**	**30 Sep 24**	**30 Sep 23**	**30 Sep 24**	**31 Dec 23**
Net sales	19	17	56	48	72	64
Administrative expenses	-24	-18	-75	-61	-98	-84
Operating profit/loss	**-5**	**-1**	**-19**	**-13**	**-26**	**-20**
Interest income/expenses and similar items	35	264	13	124	80	191
Profit/loss after financial items	**30**	**263**	**-6**	**111**	**54**	**171**
Appropriations	–	–	–	–	78	78
Profit/loss before taxes	**30**	**263**	**-6**	**111**	**132**	**249**
Income tax expense	–	-54	–	-23	9	-14
Profit/loss for the period	**30**	**209**	**-6**	**88**	**141**	**235**

Balance sheet

Balance sheet, SEKm	**30 Sep 24**	**31 Dec 23**	**30 Sep 23**
Intangible non-current assets	0	0	0
Tangible non-current assets	0	0	0
Non-current financial assets	7,699	7,804	7,711
Total non-current assets	**7,699**	**7,804**	**7,711**
Current receivables	593	593	669
Total current assets	**593**	**593**	**669**
Total assets	**8,292**	**8,397**	**8,380**
Restricted equity	62	62	62
Unrestricted equity	2,563	2,642	2,494
Total equity	**2,625**	**2,704**	**2,556**
Interest-bearing long-term liabilities	3,673	2,560	2,659
Non-interest-bearing long-term liabilities	2	2	2
Total long-term liabilities	**3,675**	**2,562**	**2,661**
Interest-bearing short-term liabilities	1,958	2,994	3,126
Non-interest-bearing short-term liabilities	34	137	37
Total short-term liabilities	**1,992**	**3,131**	**3,163**
Total equity and liabilities	**8,292**	**8,397**	**8,380**

Fair values on financial instruments

SEKm	30 Sep 24 Carrying amount	30 Sep 24 Level 2	30 Sep 24 Level 3	31 Dec 23 Carrying amount	31 Dec 23 Level 2	31 Dec 23 Level 3
Derivatives measured at fair value through profit or loss	0	0	–	0	0	–
Total financial assets at fair value per level	**0**	**0**	**–**	**0**	**0**	**–**
Derivatives measured at fair value through profit or loss	1	1	–	4	4	–
Contingent considerations	106	–	106	87	–	87
Total financial liabilities at fair value per level	**107**	**1**	**106**	**91**	**4**	**87**

The fair value and carrying amount are recognized in the balance sheet as shown in the table above.
For quoted securities, the fair value is determined on the basis of the asset's quoted price in an active market, level 1. At the reporting date the Group had no items in this category. For currency contracts and embedded derivatives, the fair value is determined on the basis of observable market data, level 2. For contingent considerations, a cash flow-based valuation is performed, which is not based on observable market data, level 3. For the Group's other financial assets and liabilities, fair value is estimated to essentially correspond to the carrying amount.

Contingent considerations

	3 months ending		9 months ending		12 months ending	
SEKm	30 Sep 24	30 Sep 23	30 Sep 24	30 Sep 23	30 Sep 24	31 Dec 23
Carrying amount, opening balance	**41**	**164**	**87**	**266**	**146**	**266**
Acquisitions during the period	62	5	62	5	62	5
Consideration paid	-1	–	-42	-16	-42	-16
Revaluation through profit or loss	3	1	3	1	4	2
Reversed through profit or loss	–	-18	-7	-101	-53	-147
Interest expenses	1	-1	1	-3	-4	-8
Exchange differences	0	-5	2	-6	-7	-15
Carrying amount, closing balance	**106**	**146**	**106**	**146**	**106**	**87**

Pledged assets and contingent liabilities in the Group

SEKm	30 Sep 24	31 Dec 23	30 Sep 23
Contingent liabilities	53	51	52

AddLife

Reconciliation key ratios

Return on equity	**Profit/loss after tax attributable to shareholders, as a percentage of shareholders' proportion of average equity.**		
	30 Sep 24	**31 Dec 23**	**30 Sep 23**
Profit/loss for the period (roll 12 months)	119	192	295
Average equity	5,123	5,117	5,083
Return on equity	**119/5,123=2%**	**192/5,117=4%**	**295/5,083=6%**

Return on working capital (P/WC)	**EBITA in relation to average working capital.**		
	30 Sep 24	**31 Dec 23**	**30 Sep 23**
EBITA	1,091	1,135	1,115
Average working capital (WC)	2,310	2,290	2,261
P/WC	**1,091/2,310=47%**	**1,135/2,290=50%**	**1,115/2,261=49%**

EBITDA	**Operating profit before depreciation, amortization and write-down.**		
	30 Sep 24	**31 Dec 23**	**30 Sep 23**
Operating profit (12 months rolling)	551	585	675
Depreciation, amortization and write-down	930	919	779
EBITDA	**1,481**	**1,504**	**1,454**

EBITA	**Operating profit before amortization and write-down of intangible assets.**		
	30 Sep 24	**31 Dec 23**	**30 Sep 23**
Operating profit (12 months rolling)	551	585	675
Amortization and write-down of intangible assets	541	550	440
EBITA	**1,091**	**1,135**	**1,115**

EBITA-margin	**EBITA in relation to net sales**		
	30 Sep 24	**31 Dec 23**	**30 Sep 23**
EBITA	1,091	1,135	1,115
Net sales (12 months rolling)	10,012	9,685	9,467
EBITA-margin	**1,091/10,012=10.9%**	**1,135/9,685=11.7%**	**1,115/9,467=11.8%**

Definitions

EBITA	Operating profit before amortization and write-down of intangible assets.
EBITDA	Operating profit before depreciation, amortization and write-down
Equity per share	Shareholders' proportion of equity divided by the number of shares outstanding at the end of the reporting period
Cash flow per share	Cash flow from operating activities, divided by the average number of shares.
Net debt/equity ratio	Financial net liabilities in relation to shareholders' equity
Earnings per share (EPS)	Shareholders' proportion of profit/loss for the year in relation to the average number of shares outstanding
Profit growth EBITA	This year's EBITA decreased by last year's EBITA divided by last year's EBITA.
Financial net liabilities	Interest-bearing liabilities and interest-bearing provisions, less cash and cash equivalents.
Equity ratio	Equity including minority interest as a percentage of total assets.

The key figures presented above are central in order to understand and evaluate AddLifes business and financial position. The key figures are presented in the "Key financial indicators table" and they are commented on in other parts of the interim report. For additional information regarding chosen key ratios, please refer to AddLife's annual report 2023.
The comparison figures for income and expense items relate to values for the period January–September 2023 and for balance sheet items as at December 31, 2023 if nothing else is stated.

The share

The share capital at the end of the interim period amounted to SEK 62m (62).

The number of repurchased own shares amounts to 586,189 Class B, corresponding to 0.5 percent of the total number of shares and 0.4 percent of the votes. The average purchase price for shares held in treasury amounts to SEK 100.56 per share. The average number of treasury shares held during the interim period was 587,671 (593,951). The share price at September 30, 2024 was SEK 162.40.

SHARE DEVELOPMENT IN ADDLIFE (%)



Turnover and trading	Jan-Sep 2024
Lowest price, SEK	94.85
Highest price, SEK	168.00
Average daily turnover, SEK	16,138,937
Number of traded shares, no	25,270,206
Number of transactions, no	144,506

AddLife has three outstanding call option programmes corresponding to a total of 605,800 Class B shares. Issued call options on repurchased shares have resulted in a calculated dilution effect based on average share price for the interim period of approximately 0.0 percent (0.0). During the interim period 1,750 options in the 2020/2024 program have been redeemed, corresponding to 7,000 B shares and 243,450 options that were outstanding have been repurchased at a price corresponding to market value.

Outstanding programmes	Number of warrants	Corresponding number of shares	Percentage of total number of shares	Exercise price	Exercise period
2023/2027	205,800	205,800	0.2%	155.99	Jun 1, 2026 - Feb 26, 2027
2022/2026	150,000	150,000	0.1%	250.07	Jun 9, 2025 - Feb 27, 2026
2021/2025	250,000	250,000	0.2%	259.00	Jun 10, 2024 - Feb 28, 2025
Total	**605,800**	**605,800**			

AddLife has an outstanding incentive program based on performance shares corresponding to a maximum of 141,500 of the Company's Class B shares, which represents approximately 0.1 percent of the total number of shares. Participants receive performance shares provided that employment continues, the investment shares are retained, and the performance conditions are met. These are based on the average annual profit growth (EBITA) during the period from January 1, 2024, to December 31, 2026, as well as sustainability-related goals.

During the quarter, SEK 0 (-) million has been expensed as a result of the program.

Outstanding programme	Number of investment shares	Corresponding maximum number of performance shares	Proportion of total shares antal aktier	Vesting period
LTIP 2024	22,565	107,760	0.1%	Aug 31, 2024 - Aug 31, 2027

On September 30 2024 the number of shareholders amounted to 12,759, where of 64.06 percent are Swedish owners with respect to capital share. The 10 largest shareholders controlled 51.2 percent of number of capital and 62.3 percent of votes.

			Share in %	
Shareholders 2024-09-30	**Class A-shares**	**Class B-shares**	**of capital**	**of votes**
Roosgruppen AB	2,252,376	3,547,339	4.7	16.0
Tom Hedelius	2,066,572	23,140	1.7	12.7
AMF Fonder	0	10,715,064	8.8	6.6
SEB Fonder	0	10,374,116	8.5	6.4
Odin Fonder	0	8,430,008	6.9	5.2
Cliens Fonder	0	6,906,446	5.6	4.2
Första AP-fonden	0	6,100,000	5.0	3.7
Fidelity Mutual Funds	0	5,127,342	4.2	3.1
Vanguard Funds	0	4,157,406	3.4	2.6
Fjärde AP-fonden	0	2,897,537	2.4	1.8
Total the 10 biggest shareholders	**4,318,948**	**58,278,398**	**51.2**	**62.3**
Other shareholders	290,848	58,975,867	48.3	37.3
Total outstanding shares	**4,609,796**	**117,254,265**	**99.5**	**99.6**
Repurchased own shares Class B	-	586,189	0.5	0.4
Total registered shares	**4,609,796**	**117,840,454**	**100.0**	**100.0**

Source: Euroclear

Accounting policies

The interim report has been prepared in accordance with IFRS, applying IAS 34 Interim Financial Reporting. Disclosures according to IAS 34.16A are presented not only in the financial statements and their accompanying notes but also in other parts of the interim report. The interim report for the parent company has been prepared in accordance with the Swedish Annual Accounts Act and the Securities Market Act which is in compliance with recommendation RFR 2 Accounting for Legal Entities. The same accounting principles and basis for calculations applied as in AddLife's 2023 annual report have been applied to the interim report. The amendments to IFRSs applicable from January 1, 2024 have not had any impact on AddLife's financial reports for the interim period ended September 30, 2024.

Information on Global Minimum Tax

The group is covered by the OECD's model rules for Pillar II. Legislation on Pillar II has been adopted in Sweden, where AddLife AB is based, and entered into force on January 1, 2024. The group's exposure to legislation within Pillar II has been calculated and analyzed. The company assesses that the effect is not material as of September 30, 2024.

Alternative performance measures

AddLife presents certain financial measures in the interim report that are not defined according to IFRS. The company believes that these measures provide valuable supplemental information to investors and the company's management as they allow for evaluation of trends and the company's performance. For additional information regarding chosen key ratios, please refer to AddLife's annual report 2023. Since all companies do not calculate financial measures in the same way these are not always comparable to measures used by other companies. These financial measures should therefore not be considered as a replacement for measurements as defined under IFRS. This report provides information in greater detail regarding definitions of financial performance measures.

Transactions with related parties

No transactions with related parties that materially affected the group's financial position and earnings took place during the interim period.

Nomination Committee

At the 2024 Annual General Meeting, it was decided to authorize the Chairman of the Board to appoint members from among the representatives of the five largest shareholders by voting power as of September 30, 2024, to form a Nominating Committee together with the Chairman for the upcoming board elections. Accordingly, the following individuals have been appointed as members of the Nominating Committee: Johan Sjö, Chairman of the Board, Stefan Hedelius (appointed by Tom Hedelius), Håkan Roos (appointed by RoosGruppen AB), Hans Christian Bratterud (appointed by Odin Fonder), Andreas Wallheim (appointed by SEB Investment Management), and Patricia Hedelius (appointed by AMF). Information on how to contact the Nominating Committee is available on AddLife's website, https://www.add.life/investors/corporate-governance

Events after the end of the interim period

No significant events for the group have occurred after the end of the interim period.

Risks and uncertainties

AddLife's earnings and financial position, as well as its strategic position, are affected by various internal factors within AddLife's control and various external factors over which AddLife has limited influence. AddLife's most significant external risks are the state of the economy and market trends combined with public sector contracts and policy decisions, as well as competition. The risks and uncertainties are the same as in previous periods. For more information, see the section "Risks and uncertainties" in the administration report, in AddLife's annual report 2023. The parent company is indirectly affected by the above risks and uncertainties through its function in the group.

The geopolitical situation in Ukraine and the Middle East has not had any significant financial impact on the financial reports, but it cannot be ruled out that this will happen in the future. We are closely monitoring market developments regarding inflation, raw material, component, freight, and energy costs, as well as interest rate trends.

Stockholm October 23, 2024

Fredrik Dalborg
President and CEO

Review report

AddLife AB (publ)
Corp. id 556996-8126

Introduction

We have reviewed the condensed interim financial information (interim report) of AddLife AB (publ) as of September 30, 2024 and the nine-month period then ended. The Board of Directors and the Managing Director are responsible for the preparation and presentation of this interim report in accordance with IAS 34 and the Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our review.

Scope of review

We conducted our review in accordance with International Standard on Review Engagements ISRE 2410 Review of Interim Financial Information Performed by the Independent Auditor of the Entity. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and other generally accepted auditing practices and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the interim report is not prepared, in all material respects, for the Group in accordance with IAS 34 and the Annual Accounts Act, and for the Parent Company in accordance with the Annual Accounts Act.

Stockholm October 23, 2024

KPMG AB

Helena Nilsson
Authorized Public Accountant
Auditor in charge

KPMG AB

Susanna Norlin
Authorized Public Accountant

Video conference

Investors, analysts and the media are invited to a video conference where CEO Fredrik Dalborg and CFO Christina Rubenhag will present the interim report. The presentation will be held in English and takes about 20 minutes, after which there will be an opportunity to ask questions. It will be recorded and made available online.

The video conference will be held at 9:00 a.m. on October 23, 2024
If you wish to participate via video conference, please follow this link>>

The presentation is also available on AddLife YouTube >>

Financial calendar

- The year-end report for 1 January - 31 December 2024 will be published on February 5, 2025
- The interim report for 1 January - 31 March 2025 will be published on April 25, 2025
- The Annual General Meeting (AGM) of AddLife AB (publ) will be held on May 8, 2025, 4 PM, Stockholm
- The interim report for 1 January - 30 June 2025 will be published on July 15, 2025
- The interim report for 1 January - 30 September 2025 will be published on October 23, 2025
- The year-end report for 1 January - 31 December 2025 will be published on February 4, 2026

For further information, please contact:
Fredrik Dalborg, President and CEO, +46 70 516 09 01
Christina Rubenhag, CFO, +46 70 546 72 22

ADDLIFE IN BRIEF
AddLife is an independent provider in Life Science that offers high-quality products, services and advice to both the private and public sector in Europe. The group is divided into two business areas: Labtech and Medtech. The group comprises some 85 operating subsidiaries that provide equipment, instruments, medical devices and reagents, as well as advice and technical support to customers primarily in healthcare, research and academia, along with the food and pharmaceutical industries.

This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 7:45 a.m. CET on October 23, 2024.
AddLife AB (publ), Box 3145, Brunkebergstorg 5, SE-103 62 Stockholm. info@add.life, www.add.life,
org.nr. 556995-8126